Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
18.18 ^USD	+1.11%		-1.73%	-5.02%

Mar. 20	Myriad Genetics Gets US Patent for SneakPeek Snap Device	MT
Feb. 27	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 27, 2024 at 04:06 pm EST

Myriad Genetics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 31.2 million compared to USD 42.3 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.52 a year ago.

Latest news about Myriad Genetics, Inc.

Myriad Genetics Gets US Patent for SneakPeek Snap Device	Mar. 20	MT
Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	Feb. 27	MT
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	Feb. 27	MT
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	Feb. 27	CI
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Myriad Genetics Acquires Intermountain Precision Genomics' Assets from Intermountain Health	Feb. 01	MT
Myriad Genetics, Inc. completed the acquisition of select assets of laboratory business of Intermountain Precision Genomics.	Jan. 31	CI
Myriad Genetics Names George Daneker Jr. as President, Chief Clinical Officer of Oncology	Jan. 31	MT
Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024	Jan. 30	CI
Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	Jan. 29	MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	Jan. 29	MT
Myriad Genetics Agrees to Acquire Select Assets of Intermountain Precision Genomics' Laboratory Business	Jan. 19	MT
Myriad Genetics, Inc. agreed to acquire Select assets of Intermountain Health Care, Inc.	Jan. 17	CI
Transcript : Myriad Genetics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 04:30 PM	Jan. 10
Certain Common Stock of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024.	Jan. 07	CI
Certain Restricted Stock Units of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024.	Jan. 07	CI
Certain Options of Myriad Genetics, Inc. are subject to a Lock-Up Agreement Ending on 8-JAN-2024.	Jan. 07	CI
Myriad Genetics, Inc. Announces Chief Financial Officer Changes	Dec. 21	CI
Myriad Genetics Names Scott Leffler as Chief Financial Officer, Reiterates Outlook	Dec. 21	MT
Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	Dec. 19	MT
Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	Dec. 13	MT
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform	Nov. 16	MT

Chart Myriad Genetics, Inc.

Duration

Period

More charts

Company Profile

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâs testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Myriad Genetics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

18.18 USD

Average target price

24.08 USD

Spread / Average Target

+32.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
MYRIAD GENETICS, INC.	-5.02%	1.64B
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances